Everardo Cobos to Immunotherapy
This is a "connection" page, showing publications Everardo Cobos has written about Immunotherapy.
Connection Strength
1.392
-
Cobos C, Figueroa JA, Mirandola L, Colombo M, Summers G, Figueroa A, Aulakh A, Konala V, Verma R, Riaz J, Wade R, Saadeh C, Rahman RL, Pandey A, Radhi S, Nguyen DD, Jenkins M, Chiriva-Internati M, Cobos E. The role of human papilloma virus (HPV) infection in non-anogenital cancer and the promise of immunotherapy: a review. Int Rev Immunol. 2014 Oct; 33(5):383-401.
Score: 0.389
-
Chiriva-Internati M, Mirandola L, Yu Y, Jenkins MR, Gornati R, Bernardini G, Gioia M, Chiaramonte R, Cannon MJ, Kast WM, Cobos E. Cancer testis antigen, ropporin, is a potential target for multiple myeloma immunotherapy. J Immunother. 2011 Jul-Aug; 34(6):490-9.
Score: 0.319
-
Mirandola L, Figueroa JA, Phan TT, Grizzi F, Kim M, Rahman RL, Jenkins MR, Cobos E, Jumper C, Alalawi R, Chiriva-Internati M. Novel antigens in non-small cell lung cancer: SP17, AKAP4, and PTTG1 are potential immunotherapeutic targets. Oncotarget. 2015 Feb 20; 6(5):2812-26.
Score: 0.103
-
Mirandola L, Nguyen DD, Rahman RL, Grizzi F, Yuefei Y, Figueroa JA, Jenkins MR, Cobos E, Chiriva-Internati M. Anti-galectin-3 therapy: a new chance for multiple myeloma and ovarian cancer? Int Rev Immunol. 2014 Oct; 33(5):417-27.
Score: 0.097
-
Chiriva-Internati M, Pandey A, Saba R, Kim M, Saadeh C, Lukman T, Chiaramonte R, Jenkins M, Cobos E, Jumper C, Alalawi R. Cancer testis antigens: a novel target in lung cancer. Int Rev Immunol. 2012 Oct; 31(5):321-43.
Score: 0.087
-
Schutt C, Bumm K, Mirandola L, Bernardini G, Cunha N, Tijani L, Nguyen D, Cordero J, Jenkins MR, Cobos E, Kast WM, Chiriva-Internati M. Immunological treatment options for locoregionally advanced head and neck squamous cell carcinoma. Int Rev Immunol. 2012 Feb; 31(1):22-42.
Score: 0.083
-
Chiriva-Internati M, Mirandola L, Kast WM, Jenkins MR, Cobos E, Cannon MJ. Understanding the cross-talk between ovarian tumors and immune cells: mechanisms for effective immunotherapies. Int Rev Immunol. 2011 Apr-Jun; 30(2-3):71-86.
Score: 0.078
-
Chiriva-Internati M, Grizzi F, Wachtel MS, Jenkins M, Ferrari R, Cobos E, Frezza EE. Biological treatment for liver tumor and new potential biomarkers. Dig Dis Sci. 2008 Mar; 53(3):836-43.
Score: 0.061
-
Chiriva-Internati M, Cobos E, Kast WM. Advances in immunotherapy of multiple myeloma: from the discovery of tumor-associated antigens to clinical trials. Int Rev Immunol. 2007 May-Aug; 26(3-4):197-222.
Score: 0.060
-
Chiriva-Internati M, Grizzi F, Jumper CA, Cobos E, Hermonat PL, Frezza EE. Immunological treatment of liver tumors. World J Gastroenterol. 2005 Nov 14; 11(42):6571-6.
Score: 0.054
-
Dhasmana A, Dhasmana S, Haque S, Cobos E, Yallapu MM, Chauhan SC. Next-generation immune checkpoint inhibitors as promising functional molecules in cancer therapeutics. Cancer Metastasis Rev. 2023 09; 42(3):597-600.
Score: 0.046
-
Chiriva-Internati M, Cobos E, Da Silva DM, Kast WM. Sperm fibrous sheath proteins: a potential new class of target antigens for use in human therapeutic cancer vaccines. Cancer Immun. 2008 Apr 24; 8:8.
Score: 0.016